Histopathological responses in the CNS following inoculation with a non-neurovirulent mutant (1716) of herpes simplex virus type 1 (HSV 1): Relevance for gene and cancer therapy

Neuropathology and Applied Neurobiology

Volumn 24, Issue 5, 1998, Pages 367-372

  McKie, E A ^a   Brown, S M ^b   MacLeant, A R ^c   Grahamt, D I ^d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^c INSTITUTE OF VIROLOGY   (United Kingdom)

^d INSTITUTE OF NEUROLOGICAL SCIENCES   (United Kingdom)

Author keywords

Histopathology; HSV 1 RL1 mutants; Intracerebral inoculation

Indexed keywords

VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER THERAPY; CELL DIFFERENTIATION; CELL DIVISION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; FEMALE; GENE TARGETING; GENE THERAPY; HEMISPHERE; HERPES SIMPLEX VIRUS 1; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INOCULATION; INTRACEREBRAL DRUG ADMINISTRATION; MENINGOENCEPHALITIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS ENCEPHALITIS; VIRUS GENE; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; ANTIGENS, VIRAL; ASTROCYTES; BRAIN; BRAIN NEOPLASMS; ENCEPHALITIS, VIRAL; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; GLIAL FIBRILLARY ACIDIC PROTEIN; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; IMMUNE SYSTEM; MICE; MICE, INBRED BALB C; MUTATION;

EID: 0031727372     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2990.1998.00133.x     Document Type: Article

References (20)

1. Ahmend R, Morrison LA, Knipe DM. Persistence of viruses. In Fields Virology (3rd edn). Eds B. Fields, DM Knipe, PM Howley. Philadelphia: Lippincott-Raven, 1996: 219-49
2. Ben-Hur T, Hadar J, Shtram Y, Gilden DH, Becker Y. Neurovirulence of herpes simplex virus depends on age in mice and thymidine kinase expression. Arch Virol 1983: 78: 303-8
3. Bigami A, Dahl D. The astroglial response to stabbing. Immunofluorescence studies with antibodies to astrocytespecific protein (GFA) in mammalian and sub- mammalian species. Neuropath Appl Neurobiol 1976; 2: 248-59
4. Boloventa P, Liem RKH, Mason CA. Development of cerebellar astroglia: transitions in form and cytoskeletal content. Dev Biol 1984: 102: 248-59
5. Brown SM, Harland J, MacLean AR, Podlech J, Clements JB. Cell type and cell state determine differential In vitro growth of non-neurovirulent ICP34.5 negative herpes simplex virus. J Gen Virol 1994; 75: 2367-77
6. Chambers R, Gillespie GY, Soroceanu L et al. Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumours in a SCID mouse model of human malignant glioma. Proc Natl Acad Sci USA 1995; 92: 1411-5
7. Dahl D. The vimentin-GFA protein transition in rat neuroglia cytoskeletoh occurs at the time of myelination. J Neurosci Res 1981; 6: 741-8
8. Kesari S, Randazzo BP, Valyi-Nagy T et al. Therapy of experimental human brain tumours using a neuroattenu-ated herpes simplex virus mutant. Lab Invest 1995; 73: 636-48
9. Kesari K, Lee VM-Y. Brown SM, Trojanowski JQ. Fraser NW. Selective vulnerability of mouse CNS neurons to latent infection with a neuroattenuated herpes simplex virus. J Keurosci 1996; 16: 5644-52
10. Markert JM, Malick A, Coen DM. Martuza RL. Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex virus mutants that retain susceptibility to acyclovir. Neurosurgery 1993; 32: 597-603
11. Mathewson AJ, Berry M. Observations on the astrocyte response to a cerebral stab wound in adult rats. Brain Res 1985; 327: 61-9
12. McKie EA. MacLean AR, Lewis AD et al. Selective HI vitro replication of a herpes simplex virus type 1 (HSV-1) ICP34.5 mutant in primary human CNS tumours- evaluation of a potentially effective clinical therapy. Br J Cancer 1996; 74: 745-52
13. MacLean AR, Fareed MU, Robertson L, Harland J, Brown SM. Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence related sequences in Glasgow strain 17+ between immediate early gene 1 and the 'a' sequence. J Gen Virol 1991; 72: 631-9
14. Pyles RB, Sawtell NM, Thompson RL. Herpes simplex virus dUTPase mutants are attenuated for neurovirulence, neuroinvasiveness and reactivation from latency. J Virol 1992; 66: 6706-13
15. Randazzo RBP, Kesari K, Cesser RM et al. Treatment of intracranial murine melanoma with neuroattenuated herpes simplex virus type 1 mutant. Virology 1995; 211: 94-101
16. Taha MY, Clements GB, Brown SM. A variant of herpes simplex virus type 2 strain HG52 with a 1.5 kb deletion in RL between 0 and 0.02 and 0.81-0.83 map units is nonneurovirulent for mice. J Gen Virol 1989; 70: 705-16
17. Taha MY, Clements GB, Brown SM. The herpes simplex virus type 2 (HG52) variant JH2604 has a 1488 bp deletion which eliminates neurovirulence in mice. J Gen Virol 1989; 70: 3073-8
18. Taha MY, Brown SM, Clements JB, Graham DI. The JH2604 deletion variant of herpes simplex virus type 2 (HG52) fails to produce necrotising encephalitis following intracranial inoculation of mice. J Gen Virol 1990; 71: 1597-601
19. Thompson RL, Wagner EK. Partial rescue of herpes simplex virus neurovirulence with a 3.2 kb cloned fragment. Virus Genes 1988; 1: 261-73
20. + γ34.5 deletion mutant 1716 is avirulent in SCID mice. J Gen Virol 1994; 75: 2059-63